Abstract
The purpose of the present study was to evaluate the bioequivalence of two torasemide tablets, Torem (Roche Korea Co., Ltd., Korea, reference drug) and Torad (Samchundang Pharmaceutical Co., Ltd., Korea, test drug) tablet, according to the guidelines of Korea Food and Drug Administration (KFDA). Twenty-eight healthy male Korean volunteers, 23.68 ± 1.79 years in age and 67.59 ± 9.87 kg in body weight, were divided into two groups and received each medicine at the torasemide dose of 10 mg in a randomized 2 × 2 crossover study. After a single administration, blood samples were taken at predetermined time intervals and the serum concentrations of torasemide were monitored by an HPLC–UV. The in vitro dissolution profiles of two formulations were similar in all tested dissolution media. The pharmacokinetic parameters such as AUCt (the area under the serum concentration–time curve from time zero to 12 h), Cmax (maximum serum drug concentration), and Tmax (time to reach Cmax) were calculated, and computer programs (equiv test and K-BE test 2002) were utilized for the statistical analysis of the parameters using logarithmically transformed AUCt and Cmax. The results showed that the differences between two formulation based on the reference drug, −2.84, −1.22 and 15.91 % for AUCt, Cmax, and Tmax, respectively. No significant sequence effect was found for all of the bioavailability parameters indicating that the crossover design was properly performed. The 90 % confidence intervals using logarithmically transformed data were within the acceptance range of log0.80 to log1.25 (e.g., log0.9305−log1.0043 and log0.9422−log1.0903 for AUCt and Cmax, respectively). Thus, the criteria of the KFDA guidelines for the bioequivalence was satisfied, indicating Torad tablet and Torem tablet are bioequivalent.
References
Barroso MB, Alonso RM, Jimenez RM (2001) Simultaneous determination of torasemide and its major metabolite M5 in human urine by high-performance liquid chromatography electrochemical detection. J Chromatogr Sci 39:491–496
Cho HY, Kang HA, Park CH, Kim SM, Kim DH, Park SA, Kim KR, Hur H, Lee YB (2005) Bioequivalence of Boryung torsemide tablet to Torem tablet (torasemide 10 mg) by high performance liquid chromatography/UV detector. J Kor Pharm Sci 35:323–328
KFDA (2009) Guideline for Korean good clinical practice 2009-211
KFDA (2011) Guidance for industry, statistical approaches to establishing bioequivalence 2011-65
KFDA (2012) Guideline for bioequivalence test 2012-103
Knauf H, Mutschler E (1998) Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin Pharmacokinet 34:1–24
Lee YJ, Kim YG, Lee MG, Chung SJ, Lee MH, Shim CK (2000) Analysis of bioequivalence study using log-transformed model. Yakhakhoeji 44:308–314
Lesne M, Clerckx-Braun F, Duhoux P, van Ypersele de Strihou C (1982) Pharmacokinetic study of torasemide in humans: an overview of its diuretic effect. Int J Clin Pharmacol Ther Toxicol 20:382–387
Neugebauer G, Besenfeledr E, Möllendorff EV (1988) Pharmacokinetics and metabolism of torasemide in man. Arzneimittelforschung 38:164–166
Parfitt K, Martindale W (1999) The Martindale, 32nd edn. Pharmaceutical Press, London, p 956
Rang HP, Dale MM, Ritter JM, Moore PK (2003) Pharmacology, 5th edn. Churchill Livingstone, Philadelphia, p 362
Statistical Solutions Ltd (2001) Equiv Test® 2.0
The Korean Pharmacopoeia X (KP X) (2012) Dissolution Test 138–144
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Verternary Medicine (2001) Guidance for industry-bioanalytical method validation. http://www.fda.gov/cder/guidance/index.htm. Accessed 5 March 2011
World Medical Association Declaration of Helsinki (2008) Ethical principles for medical research involving human subjects. As amended by the 59th World Medical Assembly, Seoul, Korea. http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed 12 Dec 2011
Acknowledgments
This study was supported by a contract between Samchundang Pharm. Co. Ltd. and the Institute of Bioequivalence and Bridging Study of Chonnam National University. The authors have indicated that they have no conflicts of interest regarding the content of this article.
Author information
Authors and Affiliations
Corresponding author
Additional information
Hyun-Ah Kang and Hwa Yoon contributed equally to this work.
Rights and permissions
About this article
Cite this article
Kang, HA., Yoon, H. & Lee, YB. Bioequivalence of Torad tablet 5 mg to Torem tablet 5 mg (torasemide 5 mg). Journal of Pharmaceutical Investigation 43, 153–159 (2013). https://doi.org/10.1007/s40005-013-0063-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40005-013-0063-6